Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype
Open Access
- 23 April 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 12
Abstract
Background: Metaplastic breast cancer (MBC) is a rare and aggressive subtype of the breast. To understand the characteristics and prognosis of single hormone receptor-positive (HR+) MBC (estrogen receptor-positive [ER+]/progesterone receptor-negative [PR-] and ER-/PR+), we compared these tumors to double HR+ tumors as well as HR- tumors.Patients and Methods: The Surveillance, Epidemiology, and End Results database was used to analyze MBC between 1975 and 2016. The effect of HR status was evaluated using a multivariate Cox regression model.Results: We included 3369 patients with a median follow-up time of 42 months (range 0-322 months). In this study, 280 (8.3%) cases were double HR+ tumors, 2597 (77.1%) were double HR- tumors, and 492 (14.6%) cases were single HR+ tumors, of which 159 (4.7%) cases were ER-/PR+ tumors and 333 (9.9%) were ER+/PR- tumors. On multivariate Cox analysis, the prognosis was related to age, race/ethnicity, tumor grade, TNM stage, and surgery. HR status remained no impact on breast cancer-specific survival (BCSS). In the Kaplan-Meier curve, HR status was not associated with better BCSS or overall survival (OS). In patients without HER2 overexpression, the BCSS and OS of ER+/PR- and ER-/PR+ tumors were not significantly different from that of ER-/PR- and ER+/PR+ tumors. The difference remains no significant in patients with HER2 overexpression.Conclusions: In comparison with both ER-/PR- and ER+/PR+ tumors, we have identified clinically and biologically distinct features of single HR+ tumors. In patients with or without HER2 overexpression, the prognosis of single HR+ tumors was similar to ER-/PR- and ER+/PR+ tumors.Keywords
Funding Information
- National Natural Science Foundation of China
This publication has 32 references indexed in Scilit:
- Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicatorsWorld Journal of Surgical Oncology, 2013
- Metaplastic breast cancer: clinicopathological features and its prognosisJournal of Clinical Pathology, 2012
- The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patientsBreast Cancer Research and Treatment, 2011
- Metaplastic Breast Cancer: To Radiate or Not to Radiate?Annals of Surgical Oncology, 2010
- Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancerBreast Cancer Research and Treatment, 2010
- Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysisBreast Cancer Research and Treatment, 2008
- Basal-like carcinoma of the breast: further evidence of the possibility that most metaplastic carcinomas may be actually basal-like carcinomasMedical Molecular Morphology, 2008
- Basal carcinoma of the breast revisited: an old entity with new interpretationsJournal of Clinical Pathology, 2008
- Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literatureBreast Cancer Research and Treatment, 2006
- Metaplastic breast carcinoma: clinical–pathologic characteristics and HER2/neu expressionBreast Cancer Research and Treatment, 2005